LYMPHOQUANT
LIVE

Serial Number

87588377

Owner

INVIVOSCRIBE, INC.

Attorney

Sarah W. Matthews

First Use Date

Sep 8, 2019

Filing Date

Aug 29, 2017

Add to watchlist:

No watchlists yet
View on USPTO

LYMPHOQUANT Trademark

Serial Number: 87588377 • Registration: 6373233

LYMPHOQUANT is a trademark filed by INVIVOSCRIBE, INC. on August 29, 2017. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

INVIVOSCRIBE, INC. (37 trademarks)

10222 BARNES CANYON ROAD
SAN DIEGO, CA 92121

Entity Type: 03

Invivoscribe Technologies, Inc.

10222 Barnes Canyon Road, Building 1
San Diego, CA 921212711

Entity Type: 03

Trademark Details

Filing Date

August 29, 2017

Registration Date

June 1, 2021

First Use Anywhere

September 8, 2019

First Use in Commerce

September 8, 2019

Published for Opposition

January 30, 2018

Goods & Services

DNA analysis services for scientific research purposes, namely, DNA sequencing, bioinformatics analysis, and interpretation of biological DNA data generated from reagents and assays

DNA screening for medical purposes, namely, DNA sequencing, bioinformatics analysis, and interpretation of biological DNA data generated from reagents and assays

Assays for the treatment or diagnosis of disease; medical diagnostic reagents, namely, buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; medical diagnostic kits comprised of buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; medical diagnostic reagent kits comprised of chemical and biological reagents for the treatment, monitoring and diagnosis of disease; medical diagnostic reagent kits comprised of medical reagents for clinical or medical use; medical diagnostic assays for the treatment and diagnosis of disease; medical diagnostic assays for testing of bodily fluids

Reagents for scientific and research use, namely, buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; diagnostic reagent kits for scientific and research use comprised of buffer solutions, enzymes, molecular probes, DNA and RNA polymerases, nucleic acids, nucleic acid derivatives, primers for use in PCR, DNA templates, RNA templates, dyes and biotechnology reagents and solvents for sample preparation, purification, lysis, modification and manipulation of cells; diagnostic reagent kits for scientific and research use comprised of chemical and biological reagents for non-medical purposes; diagnostic reagents for scientific and research use; diagnostic assays for research, clinical research, and laboratory research use

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 1, 2026 REM1
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 10, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 10, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 10, 2024 REAP
REGISTERED-PRINCIPAL REGISTER
Jun 1, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Apr 28, 2021 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 27, 2021 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Apr 26, 2021 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 26, 2021 AITU
USE AMENDMENT FILED
Mar 25, 2021 IUAF
TEAS STATEMENT OF USE RECEIVED
Mar 25, 2021 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 2, 2020 EXRA
SOU EXTENSION 5 GRANTED
Oct 1, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 30, 2020 AITU
SOU EXTENSION 5 FILED
Sep 24, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Sep 24, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 27, 2020 EXRA
SOU EXTENSION 4 GRANTED
Mar 25, 2020 EX4G
SOU EXTENSION 4 FILED
Mar 25, 2020 EXT4
SOU TEAS EXTENSION RECEIVED
Mar 25, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 28, 2019 EXRA
SOU EXTENSION 3 GRANTED
Sep 26, 2019 EX3G
SOU EXTENSION 3 FILED
Sep 26, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Sep 26, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 23, 2019 EXRA
SOU EXTENSION 2 GRANTED
Mar 21, 2019 EX2G
SOU EXTENSION 2 FILED
Mar 21, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 21, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 29, 2018 EXRA
SOU EXTENSION 1 GRANTED
Sep 27, 2018 EX1G
SOU EXTENSION 1 FILED
Sep 27, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 27, 2018 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Sep 5, 2018 ASGN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 28, 2018 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 28, 2018 COAR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 27, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 30, 2018 NPUB
PUBLISHED FOR OPPOSITION
Jan 30, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 10, 2018 NONP
ASSIGNED TO LIE
Dec 26, 2017 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 5, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 5, 2017 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 5, 2017 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 5, 2017 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 5, 2017 CNEA
ASSIGNED TO EXAMINER
Dec 4, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 6, 2017 NWOS
NEW APPLICATION ENTERED
Sep 1, 2017 NWAP